China Pharma (CPHI)
China Pharma PE Ratio: 0.9208
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CPHI PE Ratio Rankings
| Overall | 99th percentile | 16 of 3152 |
| Sector | 98th percentile | 3 of 232 in Healthcare |
| Industry | 93rd percentile | 1 of 15 in Drug Manufacturers - Major |
CPHI PE Ratio Range, Past 5 Years
| Minimum | 0.9208 | May 25 2012 |
| Maximum | 8.971 | Dec 2007 |
| Average | 4.771 |
About Price to Earnings Ratio
The price to earnings ratio (PE Ratio) is the measure of the share price relative to the annual net income earned by the firm per share. PE ratio shows current investor demand for a company share. A high PE ratio generally indicates increased demand because investors anticipate earnings growth in the future. The PE ratio has units of years, which can be interpreted as the number of years of earnings to pay back purchase price.
PE ratio is often referred to as the "multiple" because it demonstrates how much an investor is willing to pay for one dollar of earnings. PE Ratios are sometimes calculated using estimations of next year's earnings per share in the denominator. When this happens, it is usually noted.
Learn More
You may also be interested in these CPHI related companies
CPHI News
Top 4 Small-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest Profit Margin
May 23, 2:27AM Benzinga
May 23, 2:27AM Benzinga
Shares of China Pharma Holdings (CPHI) trading halted on circuit breaker, shares down 12%
May 17, 12:29PM Street Insider
May 17, 12:29PM Street Insider
China Pharma Holdings, Inc. to Report First Quarter of Fiscal Year 2012 Financial Results on May 15, 2012
May 04, 8:00AM PR Newswire
May 04, 8:00AM PR Newswire
China Pharma Holdings, Inc. to Report Fiscal Year 2011 Financial Results on March 15, 2012
Mar 06, 6:00PM PR Newswire
Mar 06, 6:00PM PR Newswire
Top 4 Small-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest Revenue
Mar 02, 2:59AM Benzinga
Mar 02, 2:59AM Benzinga
China Pharma Holdings, Inc. to Report Third Quarter 2011 Financial Results on November 11, 2011
Nov 07, 8:00AM PR Newswire
Nov 07, 8:00AM PR Newswire
I like the numbers of out $CPHI this morning ... $0.23 in H1 EPS, if extrapolated, puts this at < 5X PE. Adding to cheap china stocks
about 291 days ago by AGORACOM
about 291 days ago by AGORACOM
China Pharma Holdings, Inc. Reports Second Quarter 2011 Financial Results
Aug 11, 6:00AM PR Newswire
Aug 11, 6:00AM PR Newswire
China Pharma Holdings, Inc. to Report Second Quarter 2011 Financial Results on August 11, 2011
Aug 03, 8:00AM PR Newswire
Aug 03, 8:00AM PR Newswire
China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
Jun 16, 3:53PM PR Newswire
Jun 16, 3:53PM PR Newswire
$CPHI finally moved a little..should go next week should be support around that 100dma
about 668 days ago by swtrigger
about 668 days ago by swtrigger
Time to Invest in China? http://www.superstockblog.com/time-to-invest-in-china/ $CPHI
about 805 days ago by superstockblog
about 805 days ago by superstockblog
$CPHI looking like a "newer" speculative China play; drug maker at 7.6X earnings
about 908 days ago by OptionRadar
about 908 days ago by OptionRadar
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CPHI | 0.3499 | -0.00 | -0.03% | 15.23M |
| CPHD | 38.47 | +0.38 | +1.00% | 2.519B |
| DLB | 43.96 | -0.04 | -0.09% | 4.777B |
| DLA | 14.17 | -0.03 | -0.21% | 119.74M |
| DL | 3.40 | -0.07 | -2.02% | 120.60M |
| DKA | 21.58 | -0.07 | -0.32% | |
| DK | 16.91 | +0.47 | +2.86% | 983.49M |
| DCOM | 13.34 | +0.04 | +0.30% | 469.17M |
| DCM | 15.83 | -0.05 | -0.31% | 65.64B |
| DCIX | 7.07 | -0.02 | -0.28% | 163.18M |
